Cargando…
Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
Resistance to therapy remains a major obstacle in cancer management. Although treatment with hormone and CDK4/6 inhibitors is successful in luminal breast cancer, resistance to these treatments is frequent, highlighting the need for novel therapeutic strategies to delay disease progression and impro...
Autores principales: | Rodriguez, María Jimena, Perrone, María Cecilia, Riggio, Marina, Palafox, Marta, Salinas, Valeria, Elia, Andrés, Salgueiro, Natali Daiana, Werbach, Andrea Eugenia, Marks, María Paula, Kauffman, Marcelo A., Vellón, Luciano, Serra, Violeta, Novaro, Virginia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932145/ https://www.ncbi.nlm.nih.gov/pubmed/36792625 http://dx.doi.org/10.1038/s41598-023-29425-y |
Ejemplares similares
-
Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression
por: Polo, María Laura, et al.
Publicado: (2015) -
Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016) -
Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
por: Renna, Maurizio
Publicado: (2016) -
Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014) -
Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
por: Wu, Chunjing, et al.
Publicado: (2005)